Seaview Capital Partners
QuietNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed 2014
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Seaview Capital Partners LP | 2014 | Indefinite | $34M | 30 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Jeffrey Rapaport | Quiet | None listed | 0 | 0 |
Classified sectors of Seaview Capital Partners’s own portfolio companies, based on 5 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Seaview Capital Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Caduceus Capital | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed Asia Partners | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed Genesis | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Michael Rome | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 3 |
| Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed Israel Partners | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed New Horizons | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed Partners | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Orbimed Private Investments | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| Amzl | 1 | Avenzo Therapeutics |
| Atlas Venture | 1 | Remix Therapeutics |
| Synapse Investment | 1 | Avenzo Therapeutics |
A shared board seat: a company where filings name a Seaview Capital Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.